STUDY OBJECTIVES: To examine the combined impact of sleep disordered breathing (SDB) and metabolic syndrome (MetS) in endothelial dysfunction. DESIGN: Cross-sectional assessment of endothelial function, MetS and SDB status in a population-based sample. SETTING: Community-based cohort. PARTICIPANTS: Participants (n = 431) from the Wisconsin Sleep Cohort were studied between 2004 and 2007. MetS was defined following the National Cholesterol Education Program criteria. SDB severity was defined by the apnea-hypopnea index ([AHI] events/h of sleep) during overnight polysomnography. Fasting lipids, glucose, and insulin were measured and homeostasis model assessment was calculated to quantify insulin resistance (HOMA-IR). Multivariable linear regression was used to assess associations of brachial artery flow-mediated dilation (FMD) with SDB, MetS, and their interaction. INTERVENTION: None. MEASUREMENTS AND RESULTS: Participants averaged 60.2 years of age (SD 7.8 years), 44% were female, and 97% Caucasian. MetS was present in 35%; 22% had AHI ≥ 15 events/hour. Of the no-MetS group, 7% had AHI ≥ 15 events/hour. FMD (mean 5.5%; SD 3.5%) was inversely associated with age (r = -0.16, P = 0.001) and mean brachial artery diameter (r = -0.29, P < 0.001). Multivariate linear models adjusted for CVD risk factors showed that the negative association between SDB and FMD was present among subjects with MetS (β FMD(per unit log2(AHI+1)) = -0.55%, P = 0.014), but not among subjects with normal metabolic function (β = 0.13, not significant), P for interaction = 0.011. CONCLUSION: Sleep disordered breathing and concurrent metabolic syndrome are synergistically associated with worse endothelial function. Individuals with both of these conditions appear to be at a significantly higher risk for cardiovascular disease complications.
STUDY OBJECTIVES: To examine the combined impact of sleep disordered breathing (SDB) and metabolic syndrome (MetS) in endothelial dysfunction. DESIGN: Cross-sectional assessment of endothelial function, MetS and SDB status in a population-based sample. SETTING: Community-based cohort. PARTICIPANTS: Participants (n = 431) from the Wisconsin Sleep Cohort were studied between 2004 and 2007. MetS was defined following the National Cholesterol Education Program criteria. SDB severity was defined by the apnea-hypopnea index ([AHI] events/h of sleep) during overnight polysomnography. Fasting lipids, glucose, and insulin were measured and homeostasis model assessment was calculated to quantify insulin resistance (HOMA-IR). Multivariable linear regression was used to assess associations of brachial artery flow-mediated dilation (FMD) with SDB, MetS, and their interaction. INTERVENTION: None. MEASUREMENTS AND RESULTS:Participants averaged 60.2 years of age (SD 7.8 years), 44% were female, and 97% Caucasian. MetS was present in 35%; 22% had AHI ≥ 15 events/hour. Of the no-MetS group, 7% had AHI ≥ 15 events/hour. FMD (mean 5.5%; SD 3.5%) was inversely associated with age (r = -0.16, P = 0.001) and mean brachial artery diameter (r = -0.29, P < 0.001). Multivariate linear models adjusted for CVD risk factors showed that the negative association between SDB and FMD was present among subjects with MetS (β FMD(per unit log2(AHI+1)) = -0.55%, P = 0.014), but not among subjects with normal metabolic function (β = 0.13, not significant), P for interaction = 0.011. CONCLUSION:Sleep disordered breathing and concurrent metabolic syndrome are synergistically associated with worse endothelial function. Individuals with both of these conditions appear to be at a significantly higher risk for cardiovascular disease complications.
Authors: Sanja Jelic; David J Lederer; Tessa Adams; Margherita Padeletti; Paolo C Colombo; Phillip H Factor; Thierry H Le Jemtel Journal: Circulation Date: 2010-02-16 Impact factor: 29.690
Authors: Paul E Peppard; Terry Young; Jodi H Barnet; Mari Palta; Erika W Hagen; Khin Mae Hla Journal: Am J Epidemiol Date: 2013-04-14 Impact factor: 4.897
Authors: Luciano F Drager; Heno F Lopes; Cristiane Maki-Nunes; Ivani C Trombetta; Edgar Toschi-Dias; Maria Janieire N N Alves; Raffael F Fraga; Jonathan C Jun; Carlos E Negrão; Eduardo M Krieger; Vsevolod Y Polotsky; Geraldo Lorenzi-Filho Journal: PLoS One Date: 2010-08-11 Impact factor: 3.240
Authors: Josiane L Broussard; David A Ehrmann; Eve Van Cauter; Esra Tasali; Matthew J Brady Journal: Ann Intern Med Date: 2012-10-16 Impact factor: 25.391
Authors: Ivani C Trombetta; Cristiane Maki-Nunes; Edgar Toschi-Dias; Maria-Janieire N N Alves; Maria Urbana P B Rondon; Felipe X Cepeda; Luciano F Drager; Ana Maria F W Braga; Geraldo Lorenzi-Filho; Carlos E Negrao Journal: Sleep Date: 2013-01-01 Impact factor: 5.849
Authors: Apoor S Gami; Eric J Olson; Win K Shen; R Scott Wright; Karla V Ballman; Dave O Hodge; Regina M Herges; Daniel E Howard; Virend K Somers Journal: J Am Coll Cardiol Date: 2013-06-13 Impact factor: 24.094
Authors: Edgar Toschi-Dias; Ivani C Trombetta; Valdo J D Silva; Cristiane Maki-Nunes; Felipe X Cepeda; Maria Janieire N N Alves; Glauce L Carvalho; Luciano F Drager; Geraldo Lorenzi-Filho; Carlos E Negrão; Maria Urbana P B Rondon Journal: Sleep Breath Date: 2018-06-11 Impact factor: 2.816
Authors: Sharine Wittkopp; Fen Wu; Joseph Windheim; Morgan Robinson; Kurunthachalam Kannan; Stuart D Katz; Yu Chen; Jonathan D Newman Journal: Environ Res Date: 2022-04-18 Impact factor: 8.431
Authors: James H Stein; Rebecca Stern; Jodi H Barnet; Claudia E Korcarz; Erika W Hagen; Terry Young; Paul E Peppard Journal: Sleep Breath Date: 2015-04-26 Impact factor: 2.816
Authors: Peter M Farrehi; Robert D Brook; Robert Godley; Patrick Walden; Qingmei Jiang; Melvyn Rubenfire Journal: J Clin Hypertens (Greenwich) Date: 2018-10-12 Impact factor: 3.738